Wegovy label lists dysesthesia as a side effect, most often at the 7.2 mg dose

Wegovy's prescribing information now lists dysesthesia, a term for abnormal skin sensation, among the drug's most common side effects, and the highest rate appears at the 7.2 mg dose, the newest strength on the label ^[1]. The label was revised in March 2026 ^[1].

In the adverse reactions section, dysesthesia appears on the list of reactions occurring in 5% or more of adults or pediatric patients aged 12 and older ^[1]. The label reports that 22% of patients on the 7.2 mg dose experienced altered skin sensations, compared with 6% of patients on the 2.4 mg maintenance dose and 0.3% of patients on placebo ^[1]. Those figures show the reaction was uncommon at the standard maintenance dose and rare on placebo ^[1].

Dysesthesia joins a list of common reactions that includes nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and hair loss ^[1]. The label does not describe which specific sensations the term covers, how long they last, or whether they resolve after the drug is stopped. None of that has been reported in the labeling ^[1].

The dosing picture

The 7.2 mg strength appears in the label's dosage forms and strengths section as Wegovy HD 7.2 mg, alongside pens delivering 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg ^[1]. Wegovy injection is started at 0.25 mg once weekly for four weeks, then increased every four weeks until a maintenance dose is reached ^[1]. The usual recommended maintenance dose is 2.4 mg once weekly ^[1]. The highlights do not spell out how patients move up to 7.2 mg; the label directs readers to the full prescribing information for maintenance doses by indication ^[1].

The label also covers Wegovy tablets, taken once daily on an empty stomach, with a recommended maintenance dose of 25 mg for cardiovascular risk reduction and weight reduction in adults ^[1]. This labeling change applies to Wegovy, which is semaglutide; whether other semaglutide products carry the same language has not been reported ^[1].

Other safety information in the label is unchanged. Wegovy still carries a boxed warning about thyroid C-cell tumors seen in rodents, and it remains contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 ^[1].

Why it matters for patients

Dysesthesia is not a familiar term, and the label does not translate it. Patients who notice tingling, burning, prickling or other unusual skin feelings while on semaglutide may not connect them to the drug. The dose-related pattern in the label is the practical takeaway: the reported rate at 2.4 mg was 6%, and at 7.2 mg it was 22% ^[1].

The numbers come from clinical trial experience, not from a warning about a serious organ injury ^[1]. The label lists dysesthesia among the most common reactions rather than in the warnings and precautions section, where issues such as acute pancreatitis, gallbladder disease, kidney injury from volume depletion and severe gastrointestinal reactions appear ^[1].

Whether the sensation fades with continued treatment, whether lowering the dose helps, or whether it persists after stopping the drug has not been reported in the labeling ^[1]. Patients who experience it can report it to FDA at 1-800-FDA-1088 or through the MedWatch program, and to Novo Nordisk at 1-833-934-6891 ^[1].

What happens next

The revised label is dated 03/2026 and notes that dosage and administration content was also updated that month ^[1]. The same recent-changes table shows a warning for suicidal behavior and ideation was removed in January 2026, and that warnings for acute kidney injury due to volume depletion and severe gastrointestinal reactions were added in August and October 2025 ^[1]. The label includes a postmarketing experience section, which is where side effects identified after approval are tracked ^[1]. No further label changes or FDA review dates related to dysesthesia have been disclosed ^[1].